Evidence map›Paper›PMID 32724376›Full record

ArticleOncology letters2020

MicroRNA-100 functions as a tumor suppressor in cervical cancer via downregulating the SATB1 expression and regulating AKT/mTOR signaling pathway and epithelial-to-mesenchymal transition.

Cuiping Huang, Xiaobo Qin, Na Zhao, Huijing Jin, Shuangjun Zhang, Haiyan Yang

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Cuiping HuangDepartment of Gynaecology, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Xiaobo QinDepartment of Obstetrics and Gynecology, Zhangqiu Maternity and Child Care Hospital, Jinan, Shandong 250200, P.R. China.
Na ZhaoDepartment of Imaging, People's Hospital of Rizhao, Rizhao, Shandong 276800, P.R. China.
Huijing JinWard Department, The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200, P.R. China.
Shuangjun ZhangDepartment of Radiology, The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200, P.R. China.
Haiyan YangDepartment of Interventional Medicine, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Second Hospital of Shandong University · CNZhangqiu City People's Hospital · CNPeople’s Hospital of Rizhao · CNShandong Maternal and Child Health Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer (CC) is a common malignant tumor among women worldwide, remaining the fourth most frequent cause of cancer death in women. Currently, microRNA (miRNA) is a prevalent topic in tumor-related research. The present study focused on the mechanisms of miR-100 in CC progression. qRT-PCR analysis revealed that the miR-100 expression was notably decreased in CC tissues. In addition, miR-100 downregulation was confirmed to be significantly related to the malignant clinicopathologic features of CC patients. Furthermore, miR-100 overexpression was also verified to significantly repress CC cell proliferation, migration and invasion abilities through modulating the AKT/mTOR signaling pathway and epithelial-to-mesenchymal transition. Bioinformatics analysis and luciferase reporter assay identified that special AT-rich sequence-binding protein 1 was a functional target for miR-100 in CC cells. Moreover, miR-100 overexpression was found to markedly repress the CC tumor growth

Indexed as

AKT/mTORcervical cancerepithelial-to-mesenchymal transitionmiRNA-100SATB1

Identifiers

PMID32724376
PMCPMC7377180
OpenAlexW3216887599

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.